These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12717860)

  • 1. Repression of allo-cell transplant rejection through CIITA ribonuclease P+ hepatocyte.
    Guo R; Zou P; Fan HH; Gao F; Shang QX; Cao YL; Lu HZ
    World J Gastroenterol; 2003 May; 9(5):1077-81. PubMed ID: 12717860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The biological activity of MHC classII transactivator ribonuclease P: a novel approach for hepatic transplantation rejection].
    Guo R; Zou P; Wu SS; Cao YL; Lu HZ; Fan HH; Gao F
    Zhonghua Gan Zang Bing Za Zhi; 2003 Dec; 11(12):745-8. PubMed ID: 14697138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Major histocompatibility complex class II transactivator (CIITA) hammer- head ribozyme transfer inhibits major histocompatibility complex class II (MHC-II) expression in Jukart cells].
    Guo R; Zou P; Song YP; Ma J; Lu HZ; Cao YL; Tong YJ
    Zhonghua Er Ke Za Zhi; 2003 Dec; 41(12):925-8. PubMed ID: 14723817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effects of anti-CII TA M1-RNA on IFN-gamma induced major histocompatibility complex class II antigens expression on cultured human chondrocytes.
    He F; Guo R; Du X; Lu ZS; Weng JY; Lin W
    Transpl Immunol; 2007 Jun; 17(4):231-6. PubMed ID: 17493524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Inhibitory effect of anti-C II TA RNase P on MHC II expression in Jurkat cells].
    He F; Wu SL; Sun M; Guo R
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun; 15(3):607-11. PubMed ID: 17605876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inhibition effect of CIITA anti-sense cDNA on the expression of MHCII molecules of Hela cells].
    Guo R; Zou P; Fan HH; Cui L; Cao YL; Zheng B; Gao L; Gao F; Lu HZ
    Zhonghua Xue Ye Xue Za Zhi; 2003 Dec; 24(12):636-9. PubMed ID: 14761611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of human anti-porcine T-cell immune responses by major histocompatibility complex class II transactivator constructs lacking the amino terminal domain.
    Yun S; Gustafsson K; Fabre JW
    Transplantation; 1998 Jul; 66(1):103-11. PubMed ID: 9679829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biological activity of C II TA anti-sense RNA--a novel approach to inhibition of rejection in transplantation].
    Guo R; Zou P; Du X; Zhag M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):848-51. PubMed ID: 16277856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro biological activity of anti-C II TA hammerhead ribozyme--a novel approach for autoimmune diseases.
    Liu F; Zou P; Guo R; Lu H; Fan H
    J Huazhong Univ Sci Technolog Med Sci; 2003; 23(4):335-8. PubMed ID: 15015629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines.
    Rodríguez T; Méndez R; Del Campo A; Aptsiauri N; Martín J; Orozco G; Pawelec G; Schadendorf D; Ruiz-Cabello F; Garrido F
    Immunogenetics; 2007 Feb; 59(2):123-33. PubMed ID: 17180681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulating immunogenicity of Schwann cells via inhibiting a potential target of class II transactivator (CIITA) gene.
    Yang Y; Dai W; Chen Z; Yan Z; Yao Z; Zhang C
    Biosci Trends; 2013 Feb; 7(1):50-5. PubMed ID: 23524893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed allograft rejection by the suppression of class II transactivator.
    Kim TW; Choi YM; Seo JN; Kim JH; Suh YH; Chung DH; Jung KC; Oh KI
    Exp Mol Med; 2006 Jun; 38(3):210-6. PubMed ID: 16819279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The expression and significance of major histocompatibility complex II transactivator gene in five human malignant hematological cell lines].
    You Y; Zou P; Guo R
    Zhonghua Nei Ke Za Zhi; 2004 Apr; 43(4):288-91. PubMed ID: 15130416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity.
    Sartoris S; Valle MT; Barbaro AL; Tosi G; Cestari T; D'Agostino A; Megiovanni AM; Manca F; Accolla RS
    J Immunol; 1998 Jul; 161(2):814-20. PubMed ID: 9670958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cloning and biological activities of riboenzymes against major histocompatibility complex class II transactivator].
    Guo R; Zou P; Yang XC; Lu HZ; Gao F; Cao YL; Zhang M; Fan HH
    Zhonghua Yi Xue Za Zhi; 2003 Apr; 83(8):669-72. PubMed ID: 12887826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells.
    Meissner M; Whiteside TL; Kaufmann R; Seliger B
    Arch Dermatol Res; 2009 Feb; 301(2):189-93. PubMed ID: 19104823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of class II transactivator with HLA-DR antigen and its implications.
    Xu KL; Li H; Pan XY; Li ZY; Lu QX; Zhang Y; Zhu HH; DU B; Zeng LY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):147-51. PubMed ID: 17490542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuation of allograft rejection by intragraft inhibition of class II transcativator in high responder rat liver transplantation.
    Liu G; He X; Lu N; Qiu Y; Wang H
    Microsurgery; 2015 Jan; 35(1):52-9. PubMed ID: 24764281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class II transactivator knockdown limits major histocompatibility complex II expression, diminishes immune rejection, and improves survival of allogeneic bone marrow stem cells in the infarcted heart.
    Huang XP; Ludke A; Dhingra S; Guo J; Sun Z; Zhang L; Weisel RD; Li RK
    FASEB J; 2016 Sep; 30(9):3069-82. PubMed ID: 27221978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment.
    Cobaleda C; Sánchez-García I
    Blood; 2000 Feb; 95(3):731-7. PubMed ID: 10648380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.